Forget EU, SNTS knows how to do market research and know they can sell Ruconest for acute HAE. They are also POSSIBLY going for the additional indications of prophylaxis for HAE and pancreatitis (no drug available per Cowen CC). Cinryze from VPHM already sells $300 million annually to treat HAE by prophylaxis (2 times a week administration), and that is only for a small portion of HAE population. Cinryze is derived from human blood, so there is also concerns of contamination by disease and it is expensive to purify and difficult to get the product sometimes. Ruconest comes from rabbits, so no chance of human virus contamination and cheaper to prepare. It is prepared somewhere in Europe, so they probably have the market kept from a smaller Pharming. There are also possible governmental issues, where EU has little to spend. BUY know the stock is coming out from very cheap low $15's. KABOOM back up can happen any time, who wants to chase?